Priapism Emergency Management: What to Do, When to Act, and How to Prevent It

What Priapism Actually Is and Why the Clock Matters

Priapism is a prolonged, often painful erection unrelated to sexual stimulation. Ischemic (low-flow) priapism accounts for roughly 95% of all cases and is a compartment syndrome of the penis. Blood pools, oxygen falls, pH drops, and cavernosal smooth muscle begins to necrose. The American Urological Association (AUA) and the European Association of Urology both define the four-hour mark as the threshold requiring emergency intervention. [1]

After six hours, hypoxic damage to cavernosal endothelium is measurable. After 24 hours, studies show fibrosis rates approaching 90%, which translates to permanent erectile dysfunction in a substantial proportion of patients. [2] A 2013 analysis published in the Journal of Sexual Medicine found that men treated within six hours had significantly better erectile function outcomes than those presenting after twelve hours, with the odds of natural erectile recovery dropping below 50% once the duration crossed the twelve-hour mark. [3]

Non-ischemic (high-flow) priapism, caused by an arteriovenous fistula typically following perineal trauma, is not a same-day emergency in the same sense. The cavernosa remain oxygenated. Still, definitive embolization or ligation is typically required, and urologic referral within 24 to 48 hours is appropriate. [4]

Stuttering priapism, characterized by recurrent self-resolving episodes under four hours, deserves mention because it often predicts a major ischemic episode and requires prophylactic management, commonly with PDE5 inhibitors used paradoxically at low daily doses, or with anti-androgens. [5]

The Four-Hour Rule in Practice: Step-by-Step Emergency Protocol

Reach an emergency department immediately if an erection has lasted four hours. Do not wait to see if it resolves.

The AUA guideline on priapism (updated 2021) outlines a stepwise protocol. [1] First, corporal blood gas is drawn to confirm ischemia: pH <7.25, PO2 <30 mmHg, and PCO2 >60 mmHg confirm low-flow disease. [6] Second, aspiration of 20 to 30 mL of blood per cycle decompresses the cavernosa. Third, intracavernosal phenylephrine is injected.

Phenylephrine is the preferred agent because it is a selective alpha-1 agonist with minimal beta-adrenergic cardiac effects. The AUA recommends diluting phenylephrine to 100 to 500 mcg per mL and injecting 1 mL every three to five minutes for up to one hour, with continuous cardiac monitoring. [1] The FDA-labeled indication for phenylephrine in priapism is supported by its safety profile compared with epinephrine or metaraminol, both of which carry higher cardiovascular risk. [7]

Detumescence following aspiration plus phenylephrine occurs in approximately 65 to 80% of cases when treatment begins within six hours. [8] Failure after 60 to 90 minutes of pharmacotherapy should prompt surgical shunting consultation. The Winter shunt (percutaneous cavernosal-glanular shunt) is the least invasive surgical option and is performed under local anesthesia. The Al-Ghorab and Ebbehoj techniques are alternatives depending on surgeon preference. [9]

After detumescence is achieved, the treating clinician should arrange follow-up within one week to assess erectile function with a validated instrument such as the IIEF-5, identify the precipitating cause, and adjust any offending medications.

Trimix Injections and Priapism: Dose Titration Is Non-Negotiable

Trimix is a compounded intracavernosal mixture of alprostadil (prostaglandin E1), papaverine, and phentolamine. It produces erections in roughly 90% of men with organic erectile dysfunction, including those who fail oral PDE5 inhibitors. [10] That efficacy comes with a real priapism risk if dosing is not individualized.

The mechanism is straightforward. Alprostadil relaxes smooth muscle via cyclic AMP. Papaverine inhibits phosphodiesterase non-selectively. Phentolamine blocks alpha-adrenergic tone. All three pathways converge on sustained cavernosal relaxation. An overdose, or even a correct dose in a hyper-responsive individual, can trigger ischemic priapism. [11]

Published dose-titration protocols start at the lowest available compounded concentration, typically 5/1.5/0.5 mcg per 0.1 mL for alprostadil/papaverine/phentolamine, and increase by small increments over successive office visits until the target erection duration of 30 to 60 minutes is achieved. [10] Men injecting at home must be counseled that the maximum recommended interval between injections is 24 hours, frequency should not exceed three times per week, and any erection persisting beyond four hours requires emergency care, not a second dose.

Risk factors that increase Trimix-related priapism include sickle-cell trait or disease, coagulopathies, concurrent use of anticoagulants, and psychogenic erectile dysfunction (where vascular tone is already near-normal and the drug tips the balance). A 2018 review in Translational Andrology and Urology identified inadequate initial dose titration as the single most modifiable risk factor for injection-related priapism. [12]

Fibrosis at the injection site is a separate complication. Repeated injections into the same site cause focal scarring, which can progress to Peyronie's-like plaques. Men should rotate injection sites, alternating between the left and right lateral aspects of the proximal penile shaft, avoiding the dorsal midline where the neurovascular bundle runs and the ventral midline where the urethra lies. [13]

PDE5 Inhibitor Side Effects Beyond the Headache

Sildenafil, tadalafil, vardenafil, and avanafil are first-line oral agents for erectile dysfunction per the 2023 AUA/SMSNA guideline update. [14] Their cardiovascular and visual side-effect profiles are clinically relevant and often under-explained to patients.

The most common adverse effects are vasodilatory: headache (10 to 16%), flushing (10 to 13%), nasal congestion, and transient hypotension. Combining any PDE5 inhibitor with nitrates is absolutely contraindicated because the resulting hypotension can be severe or fatal. [15] This contraindication extends to recreational nitrate use (amyl nitrite, "poppers"), a point frequently missed in clinical counseling.

Myalgia and back pain are specific to tadalafil at 20 mg, occurring in approximately 6% of users, attributed to PDE11 inhibition in skeletal muscle. [16] Sildenafil and vardenafil at standard doses produce blue-tinged vision (cyanopsia) in roughly 3% of users due to PDE6 inhibition in retinal photoreceptors. This is dose-dependent and reversible. [17]

Priapism from oral PDE5 inhibitors alone is rare, estimated at fewer than 0.5 cases per 1,000 prescriptions in the general ED population. Risk rises substantially in men with sickle-cell disease, where PDE5 inhibitors at low doses are actually used therapeutically for priapism prophylaxis due to their effect on stuttering episodes, but recreational or higher doses can precipitate sustained ischemia. [5]

NAION and PDE5 Inhibitors: Parsing the Evidence

Non-arteritic anterior ischemic optic neuropathy (NAION) causes sudden, painless, unilateral vision loss from infarction of the short posterior ciliary arteries that supply the optic nerve head. The condition affects roughly 2.3, 10.2 per 100,000 people annually in the United States. [18]

The FDA issued a safety communication in 2005 and updated drug labeling for all approved PDE5 inhibitors to include NAION as a potential risk after case reports emerged post-sildenafil approval. [19] The biological plausibility is real: PDE5 is expressed in the non-myelinated optic nerve, and vasodilation could theoretically reduce perfusion pressure at an already-vulnerable optic disc.

A 2022 case-crossover study published in JAMA Ophthalmology (N=213 NAION cases) found that PDE5 inhibitor use in the 30 days prior to NAION onset was associated with a roughly twofold increase in risk compared with the same patients' own non-exposure periods. [20] This is the most methodologically rigorous study to date, as the case-crossover design controls for fixed individual confounders.

The AUA/SMSNA guideline states: "PDE5 inhibitors should be used with caution in men with a prior episode of NAION in one eye, given the risk of involvement of the fellow eye." [14] Men with a small optic disc-to-cup ratio (the so-called "disc at risk"), hypertension, hyperlipidemia, or type 2 diabetes carry underlying susceptibility and warrant discussion before prescribing.

Clinical protocol at HealthRX: any patient reporting sudden monocular vision change while on a PDE5 inhibitor should discontinue the drug immediately and present to an ophthalmologist or emergency department the same day. Vision loss from NAION is frequently permanent.

Medication-Induced Priapism Beyond Trimix and PDE5 Inhibitors

Several other drug classes cause priapism, and patients on polypharmacy regimens deserve counseling. Trazodone, an antidepressant with alpha-adrenergic blocking properties, is one of the most commonly implicated agents, with an estimated priapism incidence of 1 in 6,000 users. [21] Antipsychotics in the phenothiazine and atypical classes (chlorpromazine, clozapine, risperidone) act through similar alpha-blockade mechanisms. [22]

Hematologic conditions merit equal attention. Sickle-cell disease carries a lifetime priapism prevalence of approximately 29 to 42% in male patients. [23] The ASPEN (Association of Priapism with Exchange Transfusion in Sickle-Cell Anemia) trial demonstrated that aggressive exchange transfusion carries its own risk, including neurologic complications, and should not be used as first-line management for isolated sickle-cell priapism without urologic co-management. [24]

Cocaine and other illicit sympathomimetics can paradoxically cause priapism through initial alpha stimulation followed by tachyphylaxis and rebound smooth-muscle relaxation. Recreational use should be documented in the clinical history. [25]

What Happens If Priapism Is Untreated or Undertreated

The natural history of untreated ischemic priapism is grim. Cavernosal biopsy data from men presenting after 24 to 48 hours show smooth muscle necrosis and collagen deposition consistent with irreversible fibrosis. [26] Long-term cohort data suggest that approximately 50% of men with ischemic priapism lasting more than 12 hours develop severe erectile dysfunction requiring penile prosthesis implantation. [3]

Penile prosthesis surgery after priapism-related fibrosis is technically more demanding than primary implantation. Scar tissue narrows the cavernosal space, requiring dilators and sometimes grafting. Complication rates including infection, cylinder erosion, and mechanical failure are approximately 1.5, 2 times higher than in fibrosis-free implantation cases. [27] The American College of Emergency Physicians includes priapism management in its list of time-sensitive urologic emergencies for this reason.

Early intervention saves erectile function. That sentence bears repeating for patients who present late because of embarrassment: the conversation with an emergency physician is brief, the intervention is manageable, and the alternative is permanent loss of natural erectile capacity.

Prevention: Before the Erection Becomes an Emergency

Structured prevention applies to every man receiving intracavernosal therapy or using PDE5 inhibitors regularly.

For Trimix users, office-based titration is the standard of care, not optional. A 2020 review in Sexual Medicine Reviews confirmed that supervised titration protocols reduce priapism-related ED visits by an estimated 70% compared with patients who self-determine starting doses. [28] Written instructions should include the four-hour rule in plain language, the address and phone number of the nearest emergency department, and a reminder that calling a telehealth provider is not a substitute for in-person care when priapism is suspected.

Pseudoephedrine 30 to 60 mg orally is sometimes recommended as a home first-aid measure for erections approaching but not yet reaching four hours in men on injection therapy. A 2014 retrospective case series in Urology found oral sympathomimetics were effective in approximately 36% of early priapism cases presenting at home. [29] This is not a reason to delay seeking emergency care if the erection persists.

For men on oral PDE5 inhibitors, keeping doses at the minimum effective level reduces both vasodilatory side effects and NAION risk. Tadalafil 5 mg daily produces adequate therapeutic response in most men and carries a lower peak plasma concentration than the 20 mg on-demand dose. [16] Any patient combining a PDE5 inhibitor with trazodone, an antipsychotic, or an alpha-blocker requires explicit counseling about the additive hypotension and priapism risks.

Sickle-cell patients should discuss hydroxyurea therapy with their hematologist if not already prescribed. Hydroxyurea reduces sickling episodes and has been shown in the MSH (Multicenter Study of Hydroxyurea in Sickle Cell Anemia) trial to reduce the frequency of painful crises, which include priapism events, by approximately 44%. [30]

Recognizing Non-Ischemic Priapism: A Different Problem Requiring Different Care

High-flow priapism, though far less common, is frequently mismanaged in emergency settings because it mimics ischemic priapism in presentation but has opposite physiology. The cavernosa are not oxygen-depleted. Penile blood gas in high-flow priapism typically shows PO2 above 90 mmHg and normal pH. [4]

Color Doppler ultrasound is the diagnostic test of choice, revealing high-velocity, turbulent arterial flow at the fistula site. Treatment is selective pudendal arteriography with embolization using absorbable gelatin sponge (Gelfoam) as the preferred agent, preserving future erectile function better than permanent embolic materials. [31] Spontaneous resolution occurs in roughly 60% of traumatic high-flow priapism cases managed conservatively, though the timeline can extend to weeks. [4]

Injecting phenylephrine into a high-flow priapism case is not only ineffective but potentially dangerous given the systemic alpha-agonist absorption risk. Accurate diagnosis before treatment prevents harm. Clinicians who are uncertain should obtain corporal blood gas before any pharmacologic intervention.